REDWOOD CITY, CA., June 21, 2022 /PRNewswire/ — Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reinventing cell therapy by developing innovative immunotherapies for patients with cancer and other terminal diseases, today announced the closing of its increased public offering of 8,050,000 ordinary shares, which includes the full exercise by the underwriters of their option to purchase an additional 1,050,000 ordinary shares, at a public price of $16.00 per share. The total gross proceeds raised under the offering were $128.8 million, before deduction of subscription discounts and commissions and offering costs, payable by Arcellx. All shares in the offer were offered by Arcellx.
BofA Securities, SVB Securities, William Blair and Canaccord Genuity acted as joint bookrunners for the offering.
Registration statements relating to the offering have been filed with the Securities and Exchange Commission and are effective as of June 15, 2022. The offering has been made solely by means of a prospectus forming part of the registration statements, copies of which may be obtained from: BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255-0001, Attention: Service Prospectus, or by email at [email protected]; or SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by phone at 1-800-808-7525, ext. 6105, or by email at [email protected]. William Blair & Company, LLC, Attn: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by phone at 1-800-621-0687, or by email at [email protected]; or Canaccord Genuity LLC, Attention: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110, or by phone at (617) 371-3900, or by email at [email protected]. Copies of the registration statements and final prospectus relating to the offering are also available at www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, and there will be no sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or territory.
About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company reinventing cell therapy by designing innovative immunotherapies for patients with cancer and other life-threatening diseases. Arcellx believes that cell therapies are one of the advanced pillars of medicine and Arcellx’s mission is to advance humanity by developing safer, more effective and more widely available cell therapies. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the United States Food and Drug Administration.
Arcellx is also advancing its doseable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, which is expected to enter the clinic in the second half of 2022.
For more information please contact: